Epoch Investment Partners Inc. Sells 26,179 Shares of Edwards Lifesciences Corporation $EW

Epoch Investment Partners Inc. lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 10.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 220,784 shares of the medical research company’s stock after selling 26,179 shares during the period. Epoch Investment Partners Inc.’s holdings in Edwards Lifesciences were worth $18,822,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after acquiring an additional 365,581 shares during the last quarter. State Street Corp raised its stake in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Edwards Lifesciences by 4.9% in the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock valued at $1,617,959,000 after buying an additional 977,933 shares during the last quarter. Norges Bank acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $803,686,000. Finally, Morgan Stanley boosted its holdings in shares of Edwards Lifesciences by 12.4% in the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock valued at $623,544,000 after buying an additional 804,942 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 620 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares in the company, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 81,038 shares of company stock worth $6,683,255 in the last quarter. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Trading Down 0.1%

NYSE EW opened at $85.02 on Monday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $89.48. The stock has a 50 day moving average of $82.77 and a 200-day moving average of $83.10. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The company has a market cap of $48.95 billion, a PE ratio of 45.22, a PEG ratio of 2.13 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the prior year, the business earned $0.64 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on EW. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. BTIG Research increased their price objective on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a report on Friday, April 24th. Evercore reissued an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a report on Friday, April 24th. TD Cowen reissued a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.